Document Detail

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
MedLine Citation:
PMID:  17949807     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Malaria remains a leading global health problem that requires the improved use of existing interventions and the accelerated development of new control methods. We aimed to assess the safety, immunogenicity, and initial efficacy of the malaria vaccine RTS,S/AS02D in infants in Africa. METHODS: We did a phase I/IIb double-blind randomised trial of 214 infants in Mozambique. Infants were randomly assigned to receive three doses either of RTS,S/AS02D or the hepatitis B vaccine Engerix-B at ages 10 weeks, 14 weeks, and 18 weeks of age, as well as routine immunisation vaccines given at 8, 12, and 16 weeks of age. The primary endpoint was safety of the RTS,S/AS02D during the first 6 months of the study, and analysis was by intention to treat. Secondary endpoints included immunogenicity and analysis of new Plasmodium falciparum infections during a 3-month follow up after the third dose. Time to new infections in the per-protocol cohort were compared between groups using Cox regression models. This study is registered with, number NCT00197028. FINDINGS: There were 17 children (15.9%; 95% CI 9.5-24.2) with serious adverse events in each group. In the follow-up which ended on March 6, 2007, there were 31 serious adverse events in the RTS,S/AS02D group and 30 serious adverse events in the Engerix-B group, none of which were reported as related to vaccination. There were four deaths during this same follow-up period; all of them after the active detection of infection period had finished at study month 6 (two in RTSS/AS02D group and two in the Engerix-B group). RTS,S/AS02D induced high titres of anti-circumsporozoite antibodies. 68 first or only P falciparum infections were documented: 22 in the RTS,S/AS02D group and 46 in the control group. The adjusted vaccine efficacy was 65.9% (95% CI 42.6-79.8%, p<0.0001). INTERPRETATION: The RTS,S/AS02D malaria vaccine was safe, well tolerated, and immunogenic in young infants. These findings set the stage for expanded phase III efficacy studies to confirm vaccine efficacy against clinical malaria disease.
John J Aponte; Pedro Aide; Montse Renom; Inacio Mandomando; Quique Bassat; Jahit Sacarlal; M Nelia Manaca; Sarah Lafuente; Arnoldo Barbosa; Amanda Leach; Marc Lievens; Johan Vekemans; Betuel Sigauque; Marie-Claude Dubois; Marie-Ange Demoitié; Marla Sillman; Barbara Savarese; John G McNeil; Eusebio Macete; W Ripley Ballou; Joe Cohen; Pedro L Alonso
Related Documents :
8078737 - Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency v...
2282187 - T-cell subsets and serum immunoglobulin levels in infants born to hiv-seropositive moth...
18773297 - Otk18 levels in plasma and cerebrospinal fluid correlate with viral load and cd8 t-cell...
24351577 - Delayed presentation of prolonged hyperinsulinaemic hypoglycaemia in a preterm small-fo...
17465987 - Indices of iron deficiency and anaemia in bedouin and jewish toddlers in southern israel.
8412347 - High-risk infant case management and assistive technology: funding and family enabling ...
Publication Detail:
Type:  Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial     Date:  2007-10-18
Journal Detail:
Title:  Lancet     Volume:  370     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-11-05     Completed Date:  2007-11-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  1543-51     Citation Subset:  AIM; IM    
Barcelona Centre for International Health Research (CRESIB), Hospital Clínic/Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Protozoan / blood
Double-Blind Method
Immunization Schedule
Malaria / prevention & control*
Malaria Vaccines / administration & dosage,  adverse effects*
Plasmodium falciparum / immunology*
Reg. No./Substance:
0/Antibodies, Protozoan; 0/Malaria Vaccines
Comment In:
Lancet. 2007 Nov 3;370(9598):1523-4   [PMID:  17980720 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Depression and school performance in middle adolescent boys and girls.
Next Document:  The influence of the cell-adhesive proteins E-cadherin and fibronectin embedded in carbonate-apatite...